Perrigo, Endo settle generic Nascobal litigation
Perrigo and Endo recently settled litigation over Endo's Nascobal (cyanocobalamin) nasal spray.
The product had a market value of $90 million for the 12 months ending June 2019, according to IQVIA.
"This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Our R&D, operations and legal teams continue to work diligently and relentlessly to introduce new generic products that provide savings to patients and healthcare systems," Perrigo executive vice president and president Rx Pharmaceuticals Sharon Kochan said.
Terms of the settlement are confidential.
The product had a market value of $90 million for the 12 months ending June 2019, according to IQVIA.
"This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Our R&D, operations and legal teams continue to work diligently and relentlessly to introduce new generic products that provide savings to patients and healthcare systems," Perrigo executive vice president and president Rx Pharmaceuticals Sharon Kochan said.
Terms of the settlement are confidential.